The volume of prescriptions reflects the scale of chronic disease management in rural healthcare systems, where millions rely on consistent access to medications. These conditions require sustained treatment, making continuity of care and medication access essential for population health.

Impaired Innovation Diffusion to Rural Areas

Even when patients in rural areas can access care for chronic conditions, differences in care quality remain. Disparities in access to glucagon-like peptide-1 (GLP-1) treatments despite their rapid adoption is a recent example that is illustrative of a broader pattern of delayed innovation diffusion to rural settings. An analysis of GLP-1 utilization in the 12 months ending January 2026, compared to the previous 12 months, shows that states with a higher share of rural residents experienced slower growth in use. Lower growth rates may reflect slower adoption, access barriers, or challenges with adherence after initiation. Vermont and Maine stand out as exceptions, with both high rurality and strong growth, pointing to the importance of local factors and the need to design community-specific approaches rather than treating rural populations as uniform.

GLP-1 growth is driven by a growing body of research demonstrating their effectiveness across multiple chronic conditions with a key role in prevention. This is particularly important in rural communities, where the most commonly treated conditions, including hypertension, diabetes, and hyperlipidemia, are major risk factors for adverse events such as stroke, heart attack, and chronic kidney disease, which these treatments can help prevent. Despite this alignment between need and potential benefit, access to GLP-1 therapies remains more limited in rural areas, reducing their impact as a preventive tool. Expanding access to these treatments represents an important opportunity to address upstream risk, improve long term outcomes, and reduce the burden of avoidable complications in rural populations. To improve gaps in access, further research should examine time to adoption, adherence rates, treatment escalation when clinically appropriate, comorbidity burden, and the underlying drivers of these patterns to inform more targeted and effective interventions.

Variations in Specialty Treatment Intensity

Examining prescriptions per patient also reveals meaningful differences in treatment intensity between rural and metro areas. Across several chronic conditions, including diabetes, hypertension, and hyperlipidemia, the number of prescriptions per patient in rural areas is approximately 10% lower than metro areas.

Gaps in treatment intensity are even more pronounced in specialty therapeutic areas, highlighting the challenges rural patients face in accessing specialized care. Immunology prescriptions decline from 7.8 prescriptions per patient in metro areas to 6.6 in rural areas, a 15% decrease. Dermatology prescriptions are similarly affected, with rural patients receiving 23% fewer prescriptions per patient. The largest disparity is seen in HIV treatment, where rural patients average 5.6 prescriptions per patient compared to 8.2 in metropolitan areas, a 31% gap.

These specialty therapeutic area disparities reflect structural barriers in rural healthcare delivery that leads to limited access for patients^6,7. Specialty care often requires referrals to providers located in distant metropolitan areas. Travel distances create access barriers, particularly for patients with limited transportation options or inflexible work schedules. The shortage of specialty providers in rural areas means fewer prescribers are available to initiate and monitor specialty medications. Technological gaps, including inconsistent broadband coverage and physician practices’ ability to afford and use advanced EHR systems, also limit the reach and effectiveness of telehealth, even as virtual care emerges as a critical tool for expanding access⁸.

The Medicaid Challenge and Healthcare System Viability

The changing payer landscape presents another serious hurdle. Rural provider revenue depends heavily on public payers, particularly Medicare Part D and Medicaid, increasing exposure to financial instability as policies shift⁹. The changing payer landscape, including Medicaid cuts, will lead to limited access if patients transition to paying for treatment out-of-pocket.

The share of branded diabetes prescriptions in 2025, a proxy for access to new evidenced-based treatment, appears similar across geographies, at 62% in metro areas and 60% in rural areas. However, a closer look at the branded proportion by payer type in rural areas highlights stark differences. Patients covered by Medicaid have the same proportion of branded prescriptions as those that live in metropolitan areas. On the other side of the spectrum, only 40% of cash prescriptions were for branded prescriptions, a rate that was 35% less than patients using Medicaid. As Medicaid work requirements under the OBBB are implemented, some patients may lose coverage, increasing the likelihood of shifting to cash pay or forgoing treatment altogether due to cost.

The economic implications extend beyond individual patient outcomes. Rural healthcare facilities, including hospitals, outpatient centers, and pharmacies, rely heavily on Medicaid funding as a significant revenue source¹⁰. Reductions in covered lives translate directly to revenue loss, threatening the sustainability of these essential access points. The loss of even a single hospital or pharmacy in a rural area can create healthcare shortages where residents must travel significant distances for basic care. Healthcare providers also represent major employers in many rural communities. Hospital closures not only eliminate access to medical services but also remove stable and well-paying jobs that anchor local economies. The ripple effects include reduced tax revenue for counties, diminished economic activity, and out-migration of skilled workers, creating downward economic spirals that prove difficult to reverse¹⁰.

From Challenge to Opportunity: The Path Forward

Rural communities are not a homogeneous population facing a single challenge. They span vast regions of the United States with diverse demographics and disease burdens. While common barriers to care exist, local context shapes how those barriers appear, making one-size-fits-all solutions ineffective and difficult to sustain.

Amid all the challenges lie real opportunities for improvement and transformation. Whether this opportunity translates to tangible improvements will depend on sustained commitment from multiple stakeholders: policymakers ensuring funding reaches communities with greatest need, healthcare providers embracing new delivery models, life sciences companies designing inclusive market access strategies, and data organizations building surveillance systems enabling evidence-driven decision making.

Given the scale and complexity of rural health issues, progress requires a practical playbook: one that aligns policy, data, and innovation across stakeholders and translates investment into tangible outcomes. The data, the policy context, and the investment resources are all aligned. The question is whether stakeholders will seize this moment to bend the curve toward health equity for rural America. To meet the moment stakeholders should:

• Establish a bridge between government and private sector partners to agree and act on priorities, invest resources, and build trust, so neither side operates in silos while addressing shared barriers. With focused federal investment, growing state‑level implementation, and innovative private‑sector engagement, the conditions now emerge to move from fragmented projects to coordinated transformation. Building that bridge is not only for scaling what works, but for sustaining rural providers, strengthening local care access points, and ensuring that innovations reach rural patients.
• Ground interventions in high-quality, integrated, and comprehensive data for sustainable outcomes. These capabilities are especially critical in rural care, where limited resources make it imperative to target innovation in the settings and communities with the greatest need. Actionable evidence is needed to enable stakeholders to understand not only who rural patients are, with demographics, payer mix, disease burden, and social determinants of health, but also how they move and improve through the health care system. A modern surveillance system is required that monitors chronic disease spread, treatment, and gaps in care in rural areas in as close to real time as possible. Such an approach is essential for monitoring the efficacy of innovative solutions funded by RHTP, so high-impact interventions can be identified and scaled nationally.
• Adapt Innovation to rural contexts, not simply deploying standardized models that worked in urban health systems. Many new therapies, technologies, and care models are built around assumptions that do not match rural realities, such as dense provider networks, high patient volumes, reliable broadband, and stable financing. In rural communities, those assumptions frequently do not hold. Stakeholders increasingly face a fundamental question: which innovations are reaching rural patients, which are not, and why? Answering such questions requires moving beyond availability to understand real‑world adoption in rural settings, where distance, workforce capacity, and resource constraints shape what is feasible. This is where data‑driven and AI‑powered insights add values. They can identify implementation barriers and inform tailored strategies that expand access while remaining operationally and financially sustainable.

References:

1. Belay B, Kraus EM, Porter R, et al. Examination of Prediabetes and Diabetes Testing Among US Pediatric Patients With Overweight or Obesity Using an Electronic Health Record. Child Obes. 2024;20(2):96-106. doi:10.1089/chi.2022.0209.
2. Weng X, Kompaniyets L, Buchacz K, et al. Hypertension Prevalence and Control Among People With and Without HIV — United States, 2022. Am J Hypertens. 2024;37(9):661-666. doi:10.1093/ajh/hpae048.
3. He S, Park S, Kuklina E, et al. Leveraging Electronic Health Records to Construct a Phenotype for Hypertension Surveillance in the United States. Am J Hypertens. 2023;36(12):677-685. doi:10.1093/ajh/hpad081.
4. He S, Park S, Fujii Y, et al. State-Level Hypertension Prevalence and Control Among Adults in the U.S. Am J Prev Med. 2024;66(1):46-54. doi:10.1016/j.amepre.2023.09.010.
5. Javed A. Bridging the Health Care Gap in Rural Populations: Challenges, Innovations, and Solutions. The American Journal of Medicine. 2025;138(5):761-762. doi:10.1016/j.amjmed.2025.01.008.
6. Evans D, Burchim S, Maris N, Patterson D. Primary Care Perspectives on Access to Specialty Care in Rural Communities: A Mixed-Method Study. The Annals of Family Medicine. 2024;22(Supplement 1). doi:10.1370/afm.22.s1.6386.
7. Wright GC, Okoye GA, Ehrlich AC, et al. Disparities in physician access for rheumatology, dermatology, and gastroenterology: a systematic review. Am J Manag Care. 2025;31(9):e270-e277. doi:10.37765/ajmc.2025.89792.
8. Liljenquist D, Weinstein JN, Lee TH. Collaborating to Affect Change for Rural Health Care with Innovation and Technology. Catalyst non-issue content. 2025;6(2). doi:10.1056/CAT.25.0133.
9. Payment & Delivery in Rural Hospitals. Accessed March 20, 2026.
10. Basu S, Patel SY, Berkowitz SA. Projected Health System and Economic Impacts of 2025 Medicaid Policy Proposals. JAMA Health Forum. 2025;6(7):e253187. doi:10.1001/jamahealthforum.2025.3187.